Rubicon Research Ltd · RUBICON · Pharma - Formulators · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 5 November 2026
Rubicon Research share price today: ₹1,658.30 at the close on 18 November 2026, up 144.6% in a year. Rubicon Research (RUBICON) is worth ₹27,454 crore, trades at a P/E of 84.3 and has closed between ₹615.20 and ₹1,860.60 over the past 52 weeks. Latest change: promoters cut their stake for 3 quarters in a row.
Rubicon Research Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer.
The main question: the share price moved +144.6% in a year while earnings per share (last four quarters) moved +76.4%. The difference came from the market paying a higher multiple.
The price has been rising for 48 weeks, and the P/E is higher than 60% of its own last 1 year. Over the last four quarters, results have been improving, with profit +66.7% on a year earlier, and 82% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.
What is the Rubicon Research share price today?
Rubicon Research Ltd's share price was ₹1,658.30 at the close on 18 November 2026. It has been rising for 48 weeks. That is 24.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹615 and ₹1,861, and at that close it sat 84% of the way up from that low.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Rubicon Research Ltd is in stage 2. The phase helps read everything below.
Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running.
Week by week since 2025: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 51 of 53 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 17 Oct 2025 | no NIFTY 500 reading |
| 24 Oct 2025 | no NIFTY 500 reading |
| 31 Oct 2025 | no NIFTY 500 reading |
| 7 Nov 2025 | no NIFTY 500 reading |
| 14 Nov 2025 | no NIFTY 500 reading |
| 21 Nov 2025 | no NIFTY 500 reading |
| 28 Nov 2025 | no NIFTY 500 reading |
| 5 Dec 2025 | no NIFTY 500 reading |
| 12 Dec 2025 | no NIFTY 500 reading |
| 19 Dec 2025 | no NIFTY 500 reading |
| 26 Dec 2025 | no NIFTY 500 reading |
| 2 Jan 2026 | no NIFTY 500 reading |
| 9 Jan 2026 | no NIFTY 500 reading |
| 16 Jan 2026 | +9.7% |
| 23 Jan 2026 | +16.8% |
| 1 Feb 2026 | +12.5% |
| 6 Feb 2026 | +25.5% |
| 13 Feb 2026 | +12.1% |
| 20 Feb 2026 | +16.7% |
| 27 Feb 2026 | +22.2% |
| 6 Mar 2026 | +26.1% |
| 13 Mar 2026 | +30.7% |
| 20 Mar 2026 | +29.3% |
| 27 Mar 2026 | +24.2% |
| 2 Apr 2026 | +30.3% |
| 10 Apr 2026 | +33.3% |
| 17 Apr 2026 | +35.7% |
| 24 Apr 2026 | +45.0% |
| 30 Apr 2026 | +44.6% |
| 8 May 2026 | +23.2% |
| 15 May 2026 | +25.8% |
| 22 May 2026 | +24.9% |
| 29 May 2026 | +31.1% |
| 4 Jun 2026 | +69.6% |
| 5 Jun 2026 | +51.4% |
| 9 Jun 2026 | +43.5% |
| 10 Jun 2026 | +47.2% |
| 12 Jun 2026 | +59.3% |
| 17 Jun 2026 | +60.1% |
| 19 Jun 2026 | +50.3% |
| 24 Jun 2026 | +45.9% |
| 25 Jun 2026 | +44.2% |
| 1 Jul 2026 | +42.3% |
| 3 Jul 2026 | +32.6% |
| 10 Jul 2026 | +47.6% |
| 17 Jul 2026 | +40.2% |
| 24 Jul 2026 | +15.1% |
| 31 Jul 2026 | +19.6% |
| 7 Aug 2026 | +27.8% |
| 14 Aug 2026 | +31.9% |
| 21 Aug 2026 | +29.0% |
| 28 Aug 2026 | +30.2% |
| 4 Sep 2026 | +29.4% |
| 11 Sep 2026 | +32.9% |
| 18 Sep 2026 | +24.8% |
| 25 Sep 2026 | +25.5% |
| 28 Sep 2026 | +28.4% |
| 1 Oct 2026 | +20.3% |
| 9 Oct 2026 | +13.9% |
| 16 Oct 2026 | +2.0% |
| 23 Oct 2026 | +4.2% |
| 30 Oct 2026 | +11.3% |
| 6 Nov 2026 | +3.1% |
| 8 Nov 2026 | +0.7% |
| 13 Nov 2026 | −7.9% |
| 18 Nov 2026 | −8.3% |
Over the last 1 year the share price moved +168% while the NIFTY 500 moved +1%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 8 November 2026. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Rubicon Research this quarter?
Three changes stood out: promoters cut their stake for 3 quarters in a row, best operating margin in 9 quarters and revenue up on a year earlier for 5 quarters in a row (every quarter we can compare).
Promoters cut their stake for 3 quarters in a row
From 60% to 51.3% of the company by the September 2026 quarter.
Best operating margin in 9 quarters
Operating margin was 25% in the September 2026 quarter, against 23% a year earlier.
Why: The margin improved because more sales came from specialty products, it won more business, and it had mostly finished exiting low margin products.
Next results: check whether the full year lands at the new 24% plus level.
From the earnings call on 5 Nov 2026.
Revenue up on a year earlier for 5 quarters in a row (every quarter we can compare)
In the September 2026 quarter revenue was ₹576 crore, +39.8% on a year earlier.
Why: Revenue rose because more product lines brought in money and specialty products held their prices.
Next results: check whether the delayed launches turn into shipments next quarter.
From the earnings call on 5 Nov 2026.
What are Rubicon Research's latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Rubicon Research reported revenue of ₹576 crore, up 39.8% from ₹412 crore a year earlier, and a profit of ₹90.0 crore, up 66.7% from ₹54.0 crore.
Rubicon Research results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹576 crore | ₹412 crore | +39.8% |
| Profit | ₹90.0 crore | ₹54.0 crore | +66.7% |
| Earnings per share | ₹5.47 | ₹3.49 | +56.7% |
| Operating margin | 25.0% | 22.8% | +2.2 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
Rubicon Research's management discussed these results on a call held on 5 November 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Rubicon Research share price history?
Rubicon Research closed at ₹1,658.30 on 18 November 2026, up 144.6% from ₹677.90 a year earlier (21 November 2025). Its highest weekly close since October 2025 was ₹1,835.40 on 11 September 2026.
Rubicon Research share price: then and now
| When | Close | Change to 18 Nov 2026 |
|---|---|---|
| 1 week ago · 11 Nov 2026 | ₹1,723.30 | −3.8% |
| 1 month ago · 19 Oct 2026 | ₹1,486.70 | +11.5% |
| 6 months ago · 15 May 2026 | ₹960.95 | +72.6% |
| 1 year ago · 21 Nov 2025 | ₹677.90 | +144.6% |
| Earliest weekly close in our records · 17 Oct 2025 | ₹618.80 | +168.0% |
| Highest weekly close since October 2025 · 11 Sep 2026 | ₹1,835.40 | −9.6% |
| Lowest weekly close since October 2025 · 24 Oct 2025 | ₹577.25 | +187.3% |
| 52-week high (weekly close) · 8 Sep 2026 | ₹1,860.60 | −10.9% |
| 52-week low (weekly close) · 8 Dec 2025 | ₹615.20 | +169.6% |
Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
66 weekly closes from 17 October 2025 to 18 November 2026.
What is the latest news on Rubicon Research?
18 Nov 2026: Rubicon Research closed at ₹1,658.30, down 3.8% on the week and up 11.5% on the month. 5 Nov 2026: Rubicon Research held its results call for July to September 2026. Management guided: FY27 operating margin at 24% plus.
Earlier
- Results for July to September 2026: Revenue up 39.8% and profit up 66.7% on a year earlier.
- 7 Aug 2026: ex-date for a dividend of ₹1.50 a share.
What dividend does Rubicon Research pay?
Rubicon Research paid ₹1.50 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.09% at the ₹1,658.30 close on 18 November 2026. The last was a dividend of ₹1.50 a share, ex-date 7 August 2026.
Rubicon Research dividends since 1 April 2021
| Ex-date | Dividend per share | Type |
|---|---|---|
| 7 Aug 2026Dividend | ₹1.50 | Dividend |
Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.
Yes. Rubicon Research Ltd paid out 10% of its profit as dividends in FY26, and it paid a dividend in 3 of its last 7 reported years. One of those years shows a negative figure because profit itself was negative.
From the exchange corporate-actions record, read 18 November 2026.
What did Rubicon Research management say on the latest results call?
On the call for July to September 2026, held on 5 November 2026, Rubicon Research's management guided: FY27 operating margin at 24% plus.
“We are happy to report that we are now guiding to 24% plus for the full year.”Parag Sancheti, on the call for July to September 2026
What management guided
- Cumulative R&D ₹500 crore over FY26 through April to June 2027 with ₹313 crore spent in 6 quarters on track.
- Pithampur revenue contribution from FY28 onward.
- Sequential dollar growth to continue in coming quarters on strong visibility.
- Arinna to return to growth then beat IPM growth before margin focus.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for July to September 2026, 5 November 2026.
What to watch in Rubicon Research's next results?
When Rubicon Research reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Delayed launches from revised export licensing converting to shipments next quarter - per shift to post-approval submissions.
Management raised each of these on the latest results call.
- Delayed launches from revised export licensing converting to shipments next quarter - per shift to post-approval submissions.
- EIR outcomes for October manufacturing inspections and July response closing cleanly - per timely-close confidence.
Which stock lists is Rubicon Research on?
Rubicon Research is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.
Is Rubicon Research profitable?
Rubicon Research Ltd earned ₹90.0 Cr of net profit in the Sep 2026 quarter, +66.7% on the same quarter a year earlier. That is the 6th quarter in a row of profit growth. Full-year FY26 profit was ₹247 Cr. Over 6 years profit has grown 30.9% a year on average. The same quarter a year earlier earned ₹54.0 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
The Sep 2026 quarter's profit is 15.6% of that quarter's revenue.
For the full year, FY26 profit was ₹247 Cr (+84.3% on the year before).
Why profit moved: revenue changed +39.8% on a year earlier and the margin moved +2.2 percentage points. Most of the change came from keeping more of each sale.
On average over the last four quarters, profit changed +92.6% and revenue +46.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.
How much revenue does Rubicon Research make, and is it growing?
Rubicon Research Ltd reported ₹576 Cr of revenue in the Sep 2026 quarter, +39.8% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 6 years it has grown 37.2% a year on average. The last full year, FY26, came in at ₹1,754 Cr.
Revenue is everything the company billed its customers in the period.
The last four reported quarters add to ₹2,100 Cr.
FY26 revenue was ₹1,754 Cr, +36.6% on the year before.
Recent pace: the last four quarters grew +46.8% on average, against 37.2% a year over the longer run, so this year is growing faster than its own long-run rate.
How much of every ₹100 of sales does Rubicon Research keep?
Rubicon Research Ltd's operating margin was 25.0% in the Sep 2026 quarter, 2.2 percentage points higher than the same quarter a year ago. Across 7 years it has been between −12.4% and 30.8%. The latest quarter is within that range.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why the margin moved: operating margin changed +2.1 percentage points on the year while gross margin changed −0.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.
Is Rubicon Research's profit turning into cash?
Over the last 3 years, 82% of Rubicon Research Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹205 Cr of operating cash against ₹247 Cr of profit.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
After ₹229 Cr of spending on assets, free cash was −₹24.0 Cr: it spent more than its operations brought in.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 82% of profit came in as cash: the cash cycle got 24 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.
What to look at next: the bigger use of cash is spending on new assets, at 2.9× depreciation over three years. The next section checks what that spending is building.
Where does Rubicon Research's cash go?
Rubicon Research Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 371 days in FY26, down from 395 days in FY21. It spent ₹355 Cr on assets over the last 3 years. Customers take 106 days to pay, and stock sits for 550 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹1,754 Cr, each day of that cycle ties up about ₹4.8 Cr, so roughly ₹1,783 Cr is tied up in the business at any time.
FY26: customers took 106 days to pay and stock sat for 550 days, about 18.1 months of sales sitting as stock, for a full cycle of 371 days, shorter than FY21's 395.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 550 days. Customers pay about 106 days after that. Suppliers are paid at 285 days. Together that makes the 371-day cycle.
Spending on assets: ₹355 Cr over the last 3 years, against ₹121 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹41.0 Cr (FY26): assets paid for that are not earning yet.
In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.
What is Rubicon Research's P/E ratio, and how does it compare with its own history?
Rubicon Research Ltd's P/E is 84.3×, in the middle of its own history: higher than 60% of past readings. Its usual P/E (the middle reading) is 76.9×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
Why the multiple is where it is: over the past year earnings per share moved +76.4% while the price moved +144.6%. The price did better than earnings, which pushed the multiple up within its own range.
In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.
Is the Rubicon Research business getting better or worse?
Rubicon Research Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: with too little history, we say so rather than guess a direction.
One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.
There are fewer than eight usable quarters, so this page does not guess a direction from so little history.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +36.6% | +64.5% | +41.0% | — |
| Profit | +84.3% | — | +51.4% | — |
| EPS | +71.4% | — | +49.2% | — |
| Share price | +128.9% | — | — | — |
How much does Rubicon Research earn on its capital?
Rubicon Research Ltd earned a ROCE of 28% in FY26. That is up from a low of −12% in FY22. Its return on capital used (ROIC) is 11.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 14.1% net margin and 0.75× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 14.1% net margin × 0.75× asset turnover × 1.81× leverage (assets divided by equity) ≈ 19.1% on equity. The margin does its share; borrowing is a big part of it.
The key test, return on capital used minus the cost of capital: 23.7% − 12.0% = +11.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
The 23.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 25.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.
Does Rubicon Research have too much debt?
Rubicon Research Ltd has total debt of ₹501 Cr against shareholder equity of ₹1,417 Cr as of Sep 2026, so its debt is 0.35× its equity. Year by year, that ratio went from 0.80 in FY25 to 0.24 in FY26. Keep that borrowing in mind when reading the returns on this page.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
What is the Rubicon Research shareholding pattern?
No group of Rubicon Research Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
How far is Rubicon Research from balance-sheet trouble?
For Rubicon Research Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Rubicon Research rank in its industry?
67.4 out of 100, rank 4 of 44 in Pharma - Formulators, with 87% of the evidence available.
Rubicon Research Ltd scores 67.4 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 4. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
The four parts add up to the total exactly: 24 + 18.8 + 8.1 + 16.5 = 67.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Rubicon Research compared with?
Rubicon Research ranks 4 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 67.4 out of 100.
- 1Marksans Pharma LtdMARKSANS · losing its lead · Most evidence points up · 78% evidence75.8out of 100
How the score adds up
Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Emcure Pharmaceuticals LtdEMCURE · leader · Most evidence points up · 75% evidence72.8out of 100
How the score adds up
Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.5× · PEG — · 15% evidenceRelative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Kwality Pharmaceuticals LtdKPL · breaking out · Most evidence points up · 75% evidence68.3out of 100
How the score adds up
Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidenceCapital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidenceValuation 6.5/20 · P/E 45.5× · PEG — · 50% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks aheadExact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 4Rubicon Research Ltd this pageRUBICON · losing its lead · Most evidence points up · 87% evidence67.4out of 100
How the score adds up
Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidenceRelative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks aheadExact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 5Accent Microcell LtdACCENTMIC · losing its lead · Most evidence points up · 65% evidence66.2out of 100
How the score adds up
Growth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 10.1/20 · P/E 25.6× · PEG — · 50% evidenceRelative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Ajanta Pharma LtdAJANTPHARM · quiet · Most evidence points up · 100% evidence65.7out of 100
How the score adds up
Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidenceRelative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. - 7Mankind Pharma LtdMANKIND · turning · Most evidence points up · 100% evidence65.3out of 100
How the score adds up
Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidenceRelative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.3out of 100
How the score adds up
Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.5/20 · P/E 44.8× · PEG — · 50% evidenceRelative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Alembic Pharmaceuticals LtdAPLLTD · leader · Evidence leans up · 85% evidence64.0out of 100
How the score adds up
Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks aheadExact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Ipca Laboratories LtdIPCALAB · leader · Evidence leans up · 82% evidence62.4out of 100
How the score adds up
Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.7/20 · P/E 33.5× · PEG — · 50% evidenceRelative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Fredun Pharmaceuticals LtdFREDUN · losing its lead · Evidence leans up · 70% evidence61.2out of 100
- 12FDC LtdFDC · turning · Evidence leans up · 75% evidence59.2out of 100
- 13Aurobindo Pharma LtdAUROPHARMA · leader · Evidence leans up · 100% evidence58.9out of 100
- 14Corona Remedies LtdCORONA · breaking out · Evidence leans up · 73% evidence58.3out of 100
- 15Lupin LtdLUPIN · quiet · Evidence leans up · 90% evidence57.2out of 100
- 16Gufic BioSciences LtdGUFICBIO · leader · Evidence leans up · 75% evidence56.8out of 100
- 17ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.0out of 100
- 18Kilitch Drugs (India) LtdKILITCH · turning · Evidence leans up · 82% evidence55.8out of 100
- 19Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 90% evidence55.2out of 100
- 20Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence54.7out of 100
- 21Influx Healthtech LtdINFLUX · quiet · Evidence leans up · 63% evidence54.3out of 100
- 22Amrutanjan Health Care LtdAMRUTANJAN · breaking out · Evidence leans up · 90% evidence54.1out of 100
- 23Akums Drugs & Pharmaceuticals LtdAKUMS · losing its lead · Evidence leans up · 75% evidence53.3out of 100
- 24Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 82% evidence52.3out of 100
- 25Zydus Lifesciences LtdZYDUSLIFE · breaking out · Evidence leans up · 90% evidence51.5out of 100
- 26Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence50.6out of 100
- 27Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Evidence leans down · 68% evidence49.1out of 100
- 28Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 82% evidence48.3out of 100
- 29J B Chemicals & Pharmaceuticals LtdJBCHEPHARM · Too little evidence to rank firmly · 59% evidence45.8out of 100
- 30Bharat Parenterals LtdBPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence45.8out of 100
- 31Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.8out of 100
- 32Bajaj Healthcare LtdBAJAJHCARE · basing · Evidence leans down · 90% evidence42.7out of 100
- 33Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.5out of 100
- 34Sun Pharmaceutical Industries LtdSUNPHARMA · quiet · Evidence leans down · 100% evidence39.8out of 100
- 35RPG Life Sciences LtdRPGLIFE · losing its lead · Evidence leans down · 90% evidence38.9out of 100
- 36Indoco Remedies LtdINDOCO · turning · Too little evidence to rank firmly · 52% evidence37.8out of 100
- 37Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence34.4out of 100
- 38Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Most evidence points down · 100% evidence34.2out of 100
- 39Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 90% evidence31.9out of 100
- 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence30.4out of 100
- 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence27.9out of 100
- 42Biocon LtdBIOCON · basing · Most evidence points down · 100% evidence22.7out of 100
- 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.4out of 100
- 44Sai Parenterals LtdSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.3out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pharma - Formulators, all 44 compared on one page.
Which companies are close to Rubicon Research in size?
Rubicon Research is the 17th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Ajanta Pharma, J B Chemicals & Pharmaceuticals and Wockhardt. Just below it: Alembic Pharmaceuticals, ERIS Lifesciences and Natco Pharma.
Pharma - Formulators companies close in size
- Ajanta Pharma Ltd ₹40,910 crore
- J B Chemicals & Pharmaceuticals Ltd ₹38,677 crore
- Wockhardt Ltd ₹32,934 crore
- Rubicon Research Ltd ₹27,451 crore
- Alembic Pharmaceuticals Ltd ₹20,528 crore
- ERIS Lifesciences Ltd ₹18,551 crore
- Natco Pharma Ltd ₹16,097 crore
All 44 Pharma - Formulators companies, largest first
Companies close in size in other industries
- Inventurus Knowledge Solutions Ltd ₹27,639 crore · IT Enabled Services/Business Process Outsourcing
- Neuland Laboratories Ltd ₹27,527 crore · Pharma - API & CRAMS
- Rubicon Research Ltd ₹27,451 crore
- Sun TV Network Ltd ₹27,442 crore · Entertainment & Media
- Godfrey Phillips India Ltd ₹27,428 crore · Cigarettes & Tobacco Products
What else do people ask about Rubicon Research?
What is Rubicon Research's share price today?
Rubicon Research Ltd's share price is ₹1,658.30, +144.6% over the past year. The whole company is worth ₹27,454 Cr on the market.
In the last 52 weeks it traded between ₹615 to ₹1,861; today it is 84% of the way up from the low, 24.5% above its 200-day average (as of 18 November 2026).
What were Rubicon Research's latest quarterly results?
Rubicon Research Ltd reported revenue of ₹576 Cr and net profit of ₹90.0 Cr for the Sep 2026 quarter. Revenue rose 39.8% and profit rose 66.7% compared with a year earlier. Earnings per share were ₹5.47.
The operating margin was 25.0%, 2.2 percentage points higher than a year earlier (as of 18 November 2026).
What is Rubicon Research's market cap?
Rubicon Research Ltd's market capitalisation is ₹27,454 Cr at a share price of ₹1,658.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).
How is Rubicon Research performing?
Rubicon Research Ltd's share price has been rising for 48 weeks. In its latest quarter, revenue rose 39.8% and profit rose 66.7% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 2 weeks running (as of 18 November 2026).
Will Rubicon Research's share price go up?
This page does not forecast Rubicon Research Ltd's share price. What it shows instead: the share price is ₹1,658.30, and it has been rising for 48 weeks. Its P/E of 84.3× is higher than 60% of its own last 1 years (as of 18 November 2026).
Who owns Rubicon Research?
Promoters own 51.3% of Rubicon Research Ltd, foreign institutions 9.0%, domestic institutions 15.7% and the public 24.0% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026).
Where is Rubicon Research in its business cycle?
Rubicon Research Ltd's FY26 operating margin was 22.8%, against a 7-year range of −12.4% to 30.8%. The latest quarter was 25.0%, near the top of its own range.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).
What could break the Rubicon Research story?
The main question: the share price moved +144.6% in a year while earnings per share (last four quarters) moved +76.4%. The difference came from the market paying a higher multiple.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).
Is Rubicon Research a stock worth studying right now?
What the numbers show: Rubicon Research Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).
Is there a Rubicon Research share price forecast for 2026?
What management itself guided: FY27 operating margin at 24% plus.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.